Breaking News
Verizon to Slash 15 Percent of Its Workforce, About 15,000 Jobs
The SCARY SHIFT from SCARCITY to ABUNDANCE
Foreclosure surge signals housing market distress as costs spiral out of control
Nearly 1,000 flights canceled despite government reopening, disruptions expected for days
Top Tech News
Blue Origin New Glenn 2 Next Launch and How Many Launches in 2026 and 2027
China's thorium reactor aims to fuse power and parity
Ancient way to create penicillin, a medicine from ancient era
Unbanked In A Connected World
Goodbye, Cavities? Scientists Just Found a Way to Regrow Tooth Enamel
Scientists Say They've Figured Out How to Transcribe Your Thoughts From an MRI Scan
SanDisk stuffed 1 TB of storage into the smallest Type-C thumb drive ever
Calling Dr. Grok. Can AI Do Better than Your Primary Physician?
HUGE 32kWh LiFePO4 DIY Battery w/ 628Ah Cells! 90 Minute Build
What Has Bitcoin Become 17 Years After Satoshi Nakamoto Published The Whitepaper?
A Brilliant New Cancer Treatment That Re-Engineers Human Cells Just Got Approved
The US Food and Drug Administration (FDA) just approved a cutting-edge cancer therapy.
On Wednesday, the FDA approved Novartis's Kymriah, also known as tisagenlecleucel, a treatment for pediatric acute lymphoblastic lymphoblastic leukemia.
"I think this is most exciting thing I've seen in my lifetime," Dr. Tim Cripe, an oncologist who was part of the FDA advisory committee panel that voted in favour of approving the drug in July.
The highly personalised treatment is called CAR T-cell therapy. It's a type of cancer immunotherapy — or a therapy that harnesses the body's immune system to take on cancer cells.
"We're entering a new frontier in medical innovation with the ability to reprogram a patient's own cells to attack a deadly cancer," FDA commissioner Scott Gottlieb said in a statement.